This HTML5 document contains 128 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n11http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q46793681
rdf:type
wikibase:Item
schema:description
bài báo khoa học artigo científico vitskapeleg artikkel articol științific scienca artikolo επιστημονικό άρθρο 2017年学术文章 บทความทางวิทยาศาสตร์ 2017年学术文章 2017年学术文章 vetenskaplig artikel 2017年学术文章 2017 nî lūn-bûn vedecký článok научная статья 2017년 논문 scientific article published on 9 October 2017 vědecký článek videnskabelig artikel 2017年學術文章 artigo científico bilimsel makale tieteellinen artikkeli artikel ilmiah artículo científico publicado en 2017 2017年学术文章 სამეცნიერო სტატია ৯ অক্টোবর ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2017年學術文章 article scientific articolo scientifico научни чланак teaduslik artikkel wissenschaftlicher Artikel научна статия мақолаи илмӣ wetenschappelijk artikel scientific article published on 9 October 2017 artikulong pang-agham 2017年学术文章 наукова стаття, опублікована в жовтні 2017 2017年學術文章 artigo científico article científic article scientifique vitenskapelig artikkel 2017 թվականի հոկտեմբերի 9-ին հրատարակված գիտական հոդված научни чланак tudományos cikk 2017年の論文 artykuł naukowy naučni članak 2017年學術文章 מאמר מדעי artículu científicu مقالة علمية نشرت في 9 أكتوبر 2017 2017年學術文章 scientific article published on 9 October 2017 artikull shkencor
p:P577
wds:Q46793681-8D8BBC41-3658-4893-91C1-EB48DAE43FC0
wdt:P577
2017-10-09T00:00:00Z
p:P407
wds:Q46793681-08A255B9-5865-43AD-8BB3-1C401F4CBF05
wdt:P407
wd:Q1860
p:P2093
wds:Q46793681-72154FD1-0EFE-47A4-8E24-A36805241FE7 wds:Q46793681-AF3A9498-F4B8-4B95-BDB2-10A0F914A8CB wds:Q46793681-C7D9B579-6C64-493F-AD73-63AB4088BDBE wds:Q46793681-EA71C1F5-305F-4FB0-882D-DC757E1D2DEB wds:Q46793681-2886B97C-2535-4A68-9854-159907912175 wds:Q46793681-0E3FAFCD-D832-479C-B70D-2BFC86C713F4
wdt:P2093
Suman Redhu Sapna Patel Douglas B Johnson Mario Sznol Zeynep Eroglu Rene Gonzalez
rdfs:label
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
skos:prefLabel
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
schema:name
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
p:P50
wds:Q46793681-0115B30A-84F9-4ED4-85F2-70F2C5CE9134 wds:Q46793681-0A26A903-BC3C-49F0-8C0E-8E702728E8A4 wds:Q46793681-1D5A7A9C-9A5C-4B5A-A808-83309357E0F6 wds:Q46793681-AD747A79-7ABA-4E94-8A58-8AAE41B0876A wds:Q46793681-B42C8BF9-FDE0-4E18-B954-A70A0B55A775 wds:Q46793681-47767D9E-A706-4B1E-86E8-4E78AA383572 wds:Q46793681-590BF00C-A350-4DC0-8155-6EBB764E7A86 wds:Q46793681-606C5E03-D6F7-4C1B-8F5F-AF87D998DF85 wds:Q46793681-72093E68-E22D-4CFA-93A1-EDD6C7670C83 wds:Q46793681-81A7EAF7-8DDE-470E-8778-92F1CFB77BA7 wds:Q46793681-BD1547F5-1F6E-4432-A361-11F1B0B1720E wds:Q46793681-DADE7F74-2564-452E-96F5-4A53429F0884 wds:Q46793681-E077E61C-0389-44BD-B117-C710D36DE992
wdt:P50
wd:Q49880375 wd:Q114439514 wd:Q117251008 wd:Q57562237 wd:Q64683306 wd:Q94947567 wd:Q42947998 wd:Q6384357 wd:Q84698958 wd:Q114522987 wd:Q117251022 wd:Q117251021 wd:Q46460242
p:P1476
wds:Q46793681-859DDCDE-3A8D-49E4-BA17-7D2533C3EFBE
wdt:P1476
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
p:P304
wds:Q46793681-AF061F21-65DA-4805-BBD3-A48709B977E7
wdt:P304
667-673
p:P31
wds:Q46793681-F6E3096F-A41E-4CBA-B405-48A3C072481A
wdt:P31
wd:Q13442814
p:P921
wds:Q46793681-2A119C5E-8B35-4AB7-A9ED-CC850DADCF99
wdt:P921
wd:Q18975855
p:P698
wds:Q46793681-B979D79F-64AA-455E-BAAB-BBB194647CD7
wdtn:P698
n10:28991513
wdt:P698
28991513
p:P1433
wds:Q46793681-701C0D3E-4301-4DA0-A06A-9DE7B0B68289
wdt:P1433
wd:Q400292
p:P433
wds:Q46793681-B7639162-F7F8-4A28-AD72-6D5A80C16A29
p:P478
wds:Q46793681-99568AC2-399F-4BD8-9C6E-7CAE10BE0C68
wdt:P433
7
wdt:P478
36
p:P356
wds:Q46793681-E1A2607F-120D-42BA-897A-9AE996EC1CB1
wdtn:P356
n11:JCO.2017.74.1025
wdt:P356
10.1200/JCO.2017.74.1025